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An estimated 7 million women in the developing world were treated for complications from unsafe abortion in 2012 (Singh and Maddow‐Zimet [2015](#sifp12049-bib-0035){ref-type="ref"}), and deaths due to complications of unsafe abortion have been estimated to account for between 8 and 18 percent of all maternal deaths (Graham et al. [2017](#sifp12049-bib-0015){ref-type="ref"}; Say et al. [2014](#sifp12049-bib-0034){ref-type="ref"}). On the other hand, there have been global declines in case‐fatality from unsafe abortions since 1990, which have in part been attributed to a shift from higher‐ to lower‐risk methods of unsafe abortion, including self‐administered medical abortion (MA) pills (Fernandez, Coeytaux, Gomez Ponce de León, and Harrison [2009](#sifp12049-bib-0010){ref-type="ref"}; World Health Organization [2011](#sifp12049-bib-0042){ref-type="ref"}). Medical abortion is a non‐surgical method of abortion administered through the use of the pharmaceutical drugs mifepristone and misoprostol, or misoprostol alone. Misoprostol is a WHO‐approved drug for MA that is widely available in pharmacies in low‐ and middle‐income countries (LMICs) as it has other indications including treatment of gastric ulcers and postpartum hemorrhage. The availability of misoprostol in pharmacies and drug shops has increased women\'s access to a safer alternative to other methods of self‐induced abortion (Hyman et al. [2013](#sifp12049-bib-0020){ref-type="ref"}), and increasing availability of misoprostol has also been linked to declining abortion‐related morbidity in some countries (Faúndes, Santos, Carvalho, and Gras [1996](#sifp12049-bib-0009){ref-type="ref"}). Misoprostol is more effective for inducing a safe abortion when used in combination with mifepristone, although a misoprostol‐only regimen is recommended where mifepristone is unavailable (World Health Organization [2012](#sifp12049-bib-0043){ref-type="ref"}). The combined regimen of mifepristone and misoprostol is also increasingly available in pharmacies in some countries, though mifepristone is much less widely available than misoprostol since its main use is for medical abortion and its registration is often therefore prevented by political sensitivities related to abortion (Culwell and Hurwitz [2013](#sifp12049-bib-0007){ref-type="ref"}).

Pharmacies and drug shops are often the first, preferred source of health care in LMICs in light of their convenience, privacy, anonymity, and low cost (Ahmed and Hossain [2007](#sifp12049-bib-0002){ref-type="ref"}; Chalker et al. [2000](#sifp12049-bib-0006){ref-type="ref"}; Goel, Ross‐Degnan, Berman, and Soumerai [1996](#sifp12049-bib-0013){ref-type="ref"}). Although a prescription is often legally required for selling misoprostol or mifepristone, sale of drugs without prescription is common in many LMICs (Goodman et al. [2007](#sifp12049-bib-0014){ref-type="ref"}). Although studies show that MA is safe, effective, and easily self‐administered in low‐resource settings (Harper et al. [2007](#sifp12049-bib-0017){ref-type="ref"}), effective use of MA drugs requires that women receive adequate information and counseling and high‐quality products (World Health Organization [2012](#sifp12049-bib-0043){ref-type="ref"}).

A review of pharmacy provision of MA, published in 2012 (Sneeringer, Billings, Ganatra, and Baird [2012](#sifp12049-bib-0037){ref-type="ref"}), found that pharmacy workers rarely offer adequate information to women buying MA. Since 2012, however, research on pharmacy and drug shop provision of MA has expanded rapidly. Moreover, the 2012 study did not take a systematic approach to the literature search, nor find evidence from intervention studies on how provision quality could be improved. The present study is a systematic review that builds on this previous work to meet two objectives: 1) to describe the level and quality of pharmacy and drug shop provision of MA in LMICs; and 2) to assess the effectiveness and cost‐effectiveness of interventions aiming to improve the level and/or quality of MA provision by pharmacy workers and drug sellers. We review the evidence both on the provision of misoprostol‐only and the mifepristone‐misoprostol combined regimen of medical abortion and on provision of other, ineffective drugs that may be sold to women seeking abortion. In addition, the term pharmacy can refer to a range of businesses of various sizes and legal status, and in this article we refer to pharmacies and drug shops as any outlet whose business is selling medicines, regardless of the training and qualifications of their staff or their legal status.

MATERIALS AND METHODS {#sifp12049-sec-0020}
=====================

Six online databases (MEDLINE, Web of Science, POPLINE, Embase, Global Health, and WHO Reproductive Health Library) were searched using standardized search terms ([Table 1](#sifp12049-supl-0001){ref-type="supplementary-material"}).[1](#sifp12049-note-0002){ref-type="fn"} For objective 1, search terms related to abortion and to pharmacies, drug sellers, or self‐medication were used (row 1 and 2, [Table 1](#sifp12049-supl-0001){ref-type="supplementary-material"}). For objective 2, additional search terms related to interventions were added (rows 1--3). Further studies (including peer‐reviewed papers and grey literature) were identified using snowball techniques applied to reference lists of identified studies.

Studies were screened for inclusion by title and abstract, were further screened by full text, and were included if they met the following criteria: outcomes met the review objectives; study design used quantitative primary data collection methods; published between 1 January 1990 and 1 April 2017; in English, Spanish, or French; LMIC setting (defined using the latest World Bank data <http://data.worldbank.org/about/country-and-lending-groups>); published peer‐reviewed articles or grey literature (published reports including a formal research element). Grey literature was considered for inclusion if a study was reported in sufficient detail to extract data and assess quality, and if there was a formal evaluation element for intervention studies. Conference abstracts were included if we could access full‐length papers with sufficient detail for quality assessment. Studies reporting provision of any type of medication intended to end a pregnancy were included, irrespective of whether the products provided were safe or effective abortifacients. Both quasi‐ and fully experimental intervention study designs were included. Abstracts and studies in French or Spanish were screened by colleagues with working proficiency in that language, and one Spanish‐language study was selected for inclusion following assessment by a co‐author fluent in the language.

Among the identified studies, data were double‐extracted using a standardized template and results were summarized narratively. For objective 1, we extracted the following data: study setting, study design (including sampling and limitations), outlet type, population outcomes measured, and comparisons made. We considered various outcomes indicating level and quality of provision, including types of abortifacients offered/sold, knowledge of and counseling on effective regimen and complications, and prescription requirements. For objective 1, methodological quality was assessed by two reviewers using a standardized checklist of ten items on prevalence design and reporting (Munn, Moola, Riitano, and Lisy [2014](#sifp12049-bib-0026){ref-type="ref"}). This checklist included recruitment, representativeness, sample size, measurement, analysis, and whether confounders and subgroups were considered (see full list and scores in [Table 2](#sifp12049-supl-0001){ref-type="supplementary-material"}). Differences in scoring were reconciled through discussion, and on the few occasions when an agreement could not be reached, a third opinion was sought. An overall index score was calculated for each study (0 points for each criteria not reported or met, 1 point if partially met, and 2 points if fully met). For studies with multiple outcomes, quality assessment of the various outcome measurements was averaged to produce an overall score. The quality of the study was considered to be low if the total score was less than 50 percent of the potential score, medium if 50--75 percent, and high if greater than 75 percent.

For objective 2, the following data were extracted: intervention description, study setting, population, study design (including any randomization procedure, sampling, and comparison group), outcome, analysis method, and results. The quality of the intervention studies for objective 2 was also assessed by two reviewers using a checklist of 11 items adapted from the Critical Appraisal Skills Programme (CASP) (<http://www.casp-uk.net/casp-tools-checklists>), amended to allow applicability to both randomized and quasi‐experimental studies (see [Table 3](#sifp12049-supl-0001){ref-type="supplementary-material"}). An overall score was calculated by giving 0 points for not meeting criteria/unknown, 1 point for partially meeting, and 2 points for meeting criteria. Study quality was graded with the following scores: 0--11, low quality; 12--17, medium quality; and 18--22, high quality. Scores were adjusted proportionally in the case of a lower denominator. Given the heterogeneity of outcomes and study designs, it was determined that meta‐analysis would not be appropriate.

RESULTS {#sifp12049-sec-0030}
=======

Objective 1: Level of Provision and Provision Practices {#sifp12049-sec-0040}
-------------------------------------------------------

### Characteristics of Studies and Study Populations {#sifp12049-sec-0050}

Figure [1](#sifp12049-fig-0001){ref-type="fig"} describes the search process for objective 1. [Table 4](#sifp12049-supl-0001){ref-type="supplementary-material"} describes the main characteristics of the 22 studies selected for inclusion for objective 1. Most (20) were peer‐reviewed journal articles, one was a conference paper (Reiss et al. [2015b](#sifp12049-bib-0031){ref-type="ref"}), and the other was a grey literature research report (Zamberlin [2007](#sifp12049-bib-0044){ref-type="ref"}). The earliest study was published in 1991 (conducted in 1985), but most were published since 2010; 13 of those had not been included in an earlier literature review on this topic (Sneeringer, Billings, Ganatra, and Baird [2012](#sifp12049-bib-0037){ref-type="ref"}). The studies were conducted in various locations in Latin America (Billings et al. [2009](#sifp12049-bib-0004){ref-type="ref"}; Bonnema and Dalebout [1992](#sifp12049-bib-0005){ref-type="ref"}; de Oddone et al. [1991](#sifp12049-bib-0008){ref-type="ref"}; Lara, Garcia, Wilson, and Paz [2011](#sifp12049-bib-0022){ref-type="ref"}; Miller et al. [2005](#sifp12049-bib-0023){ref-type="ref"}; Zamberlin [2007](#sifp12049-bib-0044){ref-type="ref"}), sub‐Saharan Africa (Adinma and Adinma [2013](#sifp12049-bib-0001){ref-type="ref"}; Akiode et al. [2010](#sifp12049-bib-0003){ref-type="ref"}; Fetters et al. [2015](#sifp12049-bib-0011){ref-type="ref"}; Hendrickson et al. [2015](#sifp12049-bib-0018){ref-type="ref"}; Reiss et al. [2017](#sifp12049-bib-0033){ref-type="ref"}) South Asia (Huda et al. [2014](#sifp12049-bib-0019){ref-type="ref"}; Mishra et al. [2016](#sifp12049-bib-0025){ref-type="ref"}; Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}; Reiss et al. [2015b](#sifp12049-bib-0031){ref-type="ref"}; Tamang, Puri, Lama, and Shrestha [2015](#sifp12049-bib-0038){ref-type="ref"}; Tamang and Tamang [2005](#sifp12049-bib-0039){ref-type="ref"}), and South East Asia (Ngo, Park, and Nguyen [2012](#sifp12049-bib-0027){ref-type="ref"}). In two of the locations, legal restrictions on abortion did not make exceptions to save the mother\'s life at the time of study (Senegal and Dominican Republic); in the majority abortion was allowed only to save the mother\'s life or to preserve her health (Nigeria, Mexico, Peru, Paraguay, Bangladesh, Kenya, and Argentina); and in the remaining locations abortion was available on socioeconomic grounds or on request (Zambia, India, Vietnam, and Nepal).

![Summary of search results for objective 1\
NOTE: MA = medical abortion. PAC = post‐abortion care.](SIFP-49-57-g001){#sifp12049-fig-0001}

The combined regimen of misoprostol and mifepristone was approved for use for MA in six of the locations at the time of study (Bangladesh, India, Zambia, Vietnam, Kenya, and Nepal) (Fetters et al. [2015](#sifp12049-bib-0011){ref-type="ref"}; Ganatra, Manning, and Pallipamulla [2005](#sifp12049-bib-0012){ref-type="ref"}; Hendrickson et al. [2015](#sifp12049-bib-0018){ref-type="ref"}; Mishra et al. [2016](#sifp12049-bib-0025){ref-type="ref"}; Ngo, Park, and Nguyen [2012](#sifp12049-bib-0027){ref-type="ref"}; Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}; Reiss et al. [2015b](#sifp12049-bib-0031){ref-type="ref"}; Reiss et al. [2016](#sifp12049-bib-0032){ref-type="ref"}; Tamang, Puri, Lama, and Shrestha [2015](#sifp12049-bib-0038){ref-type="ref"}). In all other locations misoprostol was registered for use to treat other illnesses such as gastric ulcers, but not for MA. Most studies were conducted in urban settings and involved interviews with pharmacy workers (10 studies: Adinma and Adinma [2013](#sifp12049-bib-0001){ref-type="ref"}; Akiode et al. [2010](#sifp12049-bib-0003){ref-type="ref"}; de Oddone et al. [1991](#sifp12049-bib-0008){ref-type="ref"}; Fetters et al. [2015](#sifp12049-bib-0011){ref-type="ref"}; Ganatra, Manning, and Pallipamulla [2005](#sifp12049-bib-0012){ref-type="ref"}; Mishra et al. [2016](#sifp12049-bib-0025){ref-type="ref"}; Reiss et al. [2015b](#sifp12049-bib-0031){ref-type="ref"},; Reiss et al. [2016](#sifp12049-bib-0032){ref-type="ref"}; Reiss et al. [2017](#sifp12049-bib-0033){ref-type="ref"}; Tamang and Tamang [2005](#sifp12049-bib-0039){ref-type="ref"}), mystery client surveys (where trained researchers pretend to be clients and record their experiences) (6 studies: Billings et al. [2009](#sifp12049-bib-0004){ref-type="ref"}; Hendrickson et al. [2015](#sifp12049-bib-0018){ref-type="ref"}; Huda et al. [2014](#sifp12049-bib-0019){ref-type="ref"}; Lara, Garcia, Wilson, and Paz [2011](#sifp12049-bib-0022){ref-type="ref"}; Miller et al. [2005](#sifp12049-bib-0023){ref-type="ref"}; Zamberlin [2007](#sifp12049-bib-0044){ref-type="ref"}), or a combination of the two (6 studies: Bonnema and Dalebout [1992](#sifp12049-bib-0005){ref-type="ref"}; Lara, Abuabara, Grossman, and Díaz‐Olavarrieta [2006](#sifp12049-bib-0021){ref-type="ref"}; Ngo, Park, and Nguyen [2012](#sifp12049-bib-0027){ref-type="ref"}; Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}; Reiss, Aung, Aung, and Ngo [2014](#sifp12049-bib-0029){ref-type="ref"}; Reiss et al. [2016](#sifp12049-bib-0032){ref-type="ref"}). Indicators used to report MA provision varied considerably between studies, including for example: "stocking" or "selling" MA drugs in pharmacy worker surveys, and "offering," "recommending," mentioning," and "discussing" MA drugs in mystery client surveys. Distinctions were also made between prompted and spontaneous mentions of abortifacients in two mystery client surveys (Billings et al. [2009](#sifp12049-bib-0004){ref-type="ref"}; Lara, Garcia, Wilson, and Paz [2011](#sifp12049-bib-0022){ref-type="ref"}).

Studies were conducted in a range of outlet types: some sampling frames included all outlets that sold drugs (whether registered or not) (Ganatra, Manning, and Pallipamulla [2005](#sifp12049-bib-0012){ref-type="ref"}; Huda et al. [2014](#sifp12049-bib-0019){ref-type="ref"}; Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}; Reiss, Aung, Aung, and Ngo [2014](#sifp12049-bib-0029){ref-type="ref"}); some did not specify registration status (Bonnema and Dalebout [1992](#sifp12049-bib-0005){ref-type="ref"}; Miller et al. [2005](#sifp12049-bib-0023){ref-type="ref"}; Mishra et al. [2016](#sifp12049-bib-0025){ref-type="ref"}; Zamberlin [2007](#sifp12049-bib-0044){ref-type="ref"}); and the rest used lists of registered pharmacies. Respondents were not always specified, but included salespersons, owners, or managers. Of the 13 studies that reported respondents' education or qualifications, a substantial proportion had higher education and/or specialist training. In 10 of the studies, the majority of pharmacy workers were qualified as pharmacists, had been trained to dispense medicines, or had professional training, a bachelor\'s degree, or a diploma in pharmacy. In 4 of the studies, the person invited for interview was the most senior, or the owner of the pharmacy, rather than the person most often working behind the counter.

Studies were of variable methodological quality: 7 were graded as high, 11 medium, and 4 low quality (see [Table 2](#sifp12049-supl-0001){ref-type="supplementary-material"}). Low‐quality studies typically had unrepresentative samples, inadequate recruitment methods, underpowered sample sizes, and inadequate statistical analysis.

### Level of Abortifacient Provision {#sifp12049-sec-0060}

[Table 5](#sifp12049-supl-0001){ref-type="supplementary-material"} shows data extracted on level and practice of abortifacient provision by pharmacy workers and drug sellers. The proportion of outlets offering abortifacients varied widely by setting, by legal status of abortion, and over time. High levels of provision were seen even in legally restrictive settings such as Latin America (Bonnema and Dalebout [1992](#sifp12049-bib-0005){ref-type="ref"}; Huda et al. [2014](#sifp12049-bib-0019){ref-type="ref"}; Reiss et al. [2015b](#sifp12049-bib-0031){ref-type="ref"}). In most studies where both surveys and mystery clients were used, higher provision rates were reported by the latter (Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}; Reiss, Aung, Aung, and Ngo [2014](#sifp12049-bib-0029){ref-type="ref"}, [2016](#sifp12049-bib-0032){ref-type="ref"}). Two studies found that provision was also more common when mystery clients asked directly about misoprostol or a specific brand of drug, rather than asking generally about a medication to induce abortion (Billings et al. [2009](#sifp12049-bib-0004){ref-type="ref"}; Lara, Garcia, Wilson, and Paz [2011](#sifp12049-bib-0022){ref-type="ref"}). Misoprostol‐only was the more commonly offered MA regimen, except in one recent Indian study (Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}). In sub‐Saharan Africa, self‐reported provision of misoprostol for abortion was low: less than 1 percent of pharmacies in a study in Senegal in 2013 (Reiss et al. [2017](#sifp12049-bib-0033){ref-type="ref"}) and 3 percent of pharmacies in Nigeria in 2006 (Akiode et al. [2010](#sifp12049-bib-0003){ref-type="ref"}). One mystery client study in Kenya in 2013, however, reported higher provision levels (26 percent) (Reiss et al. [2016](#sifp12049-bib-0032){ref-type="ref"}). In a repeated mystery client survey in Zambia , a significant increase in misoprostol provision was recorded, from 51 percent in 2009 to 72 percent in 2011 (Hendrickson et al. [2015](#sifp12049-bib-0018){ref-type="ref"}). Misoprostol provision to mystery clients was common in legally restrictive settings such as Latin America (which studies were of mixed quality), ranging from 78--90 percent in Mexico (Billings et al. [2009](#sifp12049-bib-0004){ref-type="ref"}; Lara, Garcia, Wilson, and Paz [2011](#sifp12049-bib-0022){ref-type="ref"}) to 64 percent in the Dominican Republic (Miller et al. [2005](#sifp12049-bib-0023){ref-type="ref"}) and 55 percent in Argentina (Zamberlin [2007](#sifp12049-bib-0044){ref-type="ref"}). In Asia, two surveys in Bangladesh (Huda et al. [2014](#sifp12049-bib-0019){ref-type="ref"}; Reiss et al. [2015b](#sifp12049-bib-0031){ref-type="ref"}) and one Indian study (Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}) also found that misoprostol provision in pharmacies and drug shops was relatively common. Provision of the mifepristone‐misoprostol combination to mystery clients was most commonly found in studies in South Asia where abortion was less legally restricted, particularly in India where 34 percent of chemists in Bihar and Jharkland reported selling the combination regimen in surveys in 2005 (Ganatra, Manning, and Pallipamulla [2005](#sifp12049-bib-0012){ref-type="ref"}), and 67 percent reported selling the combination regimen in a 2015 study (Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}).

Provision of other types of abortifacients was also reported and observed. A 2014 study in an unnamed South East Asian city, where safe, legal abortion is highly restricted, found provision of misoprostol was uncommon, and almost half of mystery clients were offered an ineffective drug: either oral or emergency contraceptives, traditional medicines, or Penorit (a hormone preparation for secondary amenorrhea designed to restore menstruation) (Reiss, Aung, Aung, and Ngo [2014](#sifp12049-bib-0029){ref-type="ref"}). In India, Nepal, and Bangladesh provision of ayurvedic and herbal abortion preparations was also commonly observed in pharmacy and drug seller surveys (Tamang and Tamang [2005](#sifp12049-bib-0039){ref-type="ref"}; Huda et al. [2014](#sifp12049-bib-0019){ref-type="ref"}; Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}). Sales of high‐dose contraceptives or hormonal injections were commonly reported by pharmacy workers and mystery clients in surveys in Latin America during the early 1990s (de Oddone et al. [1991](#sifp12049-bib-0008){ref-type="ref"}; Bonnema and Dalebout [1992](#sifp12049-bib-0005){ref-type="ref"}).

### Provision Practices and Knowledge {#sifp12049-sec-0070}

Pharmacy worker/drug seller knowledge of or counseling on an effective misoprostol‐only or mifepristone‐misoprostol regimen was poor, ranging from 3 to 17 percent in Latin America (Billings et al. [2009](#sifp12049-bib-0004){ref-type="ref"}; Lara, Abuabara, Grossman, and Díaz‐Olavarrieta [2006](#sifp12049-bib-0021){ref-type="ref"}; Lara, Garcia, Wilson, and Paz [2011](#sifp12049-bib-0022){ref-type="ref"}), from 9 to 41 percent in Asia (Ganatra, Manning, and Pallipamulla [2005](#sifp12049-bib-0012){ref-type="ref"}; Huda et al. [2014](#sifp12049-bib-0019){ref-type="ref"}; Mishra et al. [2016](#sifp12049-bib-0025){ref-type="ref"}; Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}; Reiss et al. [2015b](#sifp12049-bib-0031){ref-type="ref"}, Reiss, Aung, Aung, and Ngo [2014](#sifp12049-bib-0029){ref-type="ref"}), and from 0 to 21 percent in Africa (Hendrickson et al. [2015](#sifp12049-bib-0018){ref-type="ref"}; Reiss et al. [2016](#sifp12049-bib-0032){ref-type="ref"}; Reiss et al. [2017](#sifp12049-bib-0033){ref-type="ref"}). A recent high‐quality study in India comparing data from a mystery client study and a drug seller survey found that knowledge did not translate into accurate advice to clients: while 51 percent of pharmacy workers had correct knowledge of the dosage and timing of the combined regimen for MA, only 35 percent provided correct information to clients (Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}).

In the 8 mystery client studies reporting whether a prescription was requested, less than half of clients were asked for a prescription, ranging from none in a restrictive South East Asian city (Reiss, Aung, Aung, and Ngo [2014](#sifp12049-bib-0029){ref-type="ref"}) to 40 percent in Zambia (Hendrickson et al. [2015](#sifp12049-bib-0018){ref-type="ref"}) and Argentina (Zamberlin [2007](#sifp12049-bib-0044){ref-type="ref"}). There was also wide variation in advice given regarding potential complications in the 10 mystery client studies reporting on this indicator, ranging from 0 percent in Peru (Bonnema and Dalebout [1992](#sifp12049-bib-0005){ref-type="ref"}) to 78--100 percent in Zambia (Hendrickson et al. [2015](#sifp12049-bib-0018){ref-type="ref"}). Referral to other providers in the case of complications was low in studies from Peru and Argentina (Bonnema and Dalebout [1992](#sifp12049-bib-0005){ref-type="ref"}; Zamberlin [2007](#sifp12049-bib-0044){ref-type="ref"}) but relatively high (above 50 percent) in several studies from India (Ganatra, Manning, and Pallipamulla [2005](#sifp12049-bib-0012){ref-type="ref"}; Mishra et al. [2016](#sifp12049-bib-0025){ref-type="ref"}), Mexico (Billings et al. [2009](#sifp12049-bib-0004){ref-type="ref"}), Vietnam (Ngo, Park, and Nguyen [2012](#sifp12049-bib-0027){ref-type="ref"}), and Bangladesh (Reiss et al. [2015b](#sifp12049-bib-0031){ref-type="ref"}).

Objective 2: Interventions to Improve the Level or Quality of MA Pharmacy Provision {#sifp12049-sec-0080}
-----------------------------------------------------------------------------------

We found three studies evaluating interventions to improve the quality of pharmacy and drug shop provision of MA (see Figure [2](#sifp12049-fig-0002){ref-type="fig"} and [Table 6](#sifp12049-supl-0001){ref-type="supplementary-material"}).

![Summary of search results for objective 2: MA through pharmacy intervention studies](SIFP-49-57-g002){#sifp12049-fig-0002}

### Characteristics of Studies {#sifp12049-sec-0090}

The three studies were conducted in Zambia, Bangladesh, and Nepal. Two were reported in peer‐reviewed journals (Fetters et al. [2015](#sifp12049-bib-0011){ref-type="ref"}; Tamang, Puri, Lama, and Shrestha [2015](#sifp12049-bib-0038){ref-type="ref"}) and one was a conference abstract for which we could access the full paper (Reiss et al. [2015a](#sifp12049-bib-0030){ref-type="ref"}). The interventions evaluated included a call center (Reiss et al. [2015a](#sifp12049-bib-0030){ref-type="ref"}), training courses (Fetters et al. [2015](#sifp12049-bib-0011){ref-type="ref"}; Reiss et al. [2015a](#sifp12049-bib-0030){ref-type="ref"}; Tamang, Puri, Lama, and Shrestha [2015](#sifp12049-bib-0038){ref-type="ref"}), printed materials (Tamang, Puri, Lama, and Shrestha [2015](#sifp12049-bib-0038){ref-type="ref"}), and one‐to‐one education visits (Reiss et al. [2015a](#sifp12049-bib-0030){ref-type="ref"}). All of the interventions aimed to improve the knowledge of pharmacy workers and were graded as low quality, commonly lacking random allocation to the intervention, blinding of participants, and adequate comparisons between groups or over time (see [Table 3](#sifp12049-supl-0001){ref-type="supplementary-material"} for full scores). The study from Bangladesh was a cross‐sectional post‐intervention analytical study. The studies conducted in Zambia and Nepal were pre‐ and post‐intervention evaluations. Only one of the studies included a comparison group of pharmacies from a non‐intervention area (Tamang, Puri, Lama, and Shrestha [2015](#sifp12049-bib-0038){ref-type="ref"}). The cross‐sectional study was the only one to use probabilistic sampling and to adjust for potential confounding factors (Reiss et al. [2015a](#sifp12049-bib-0030){ref-type="ref"}). A wide range of outcomes were included in the studies ([Table 6](#sifp12049-supl-0001){ref-type="supplementary-material"}), but no studies included data on cost‐effectiveness.

### Results of Interventions {#sifp12049-sec-0100}

Training interventions were evaluated in all three studies, and reported results were positive. A one‐day training course in Zambia was associated with self‐reported increases in referrals, provision of information about MA to clients, and sales of misoprostol when participants were interviewed 12--24 months later (Fetters et al. [2015](#sifp12049-bib-0011){ref-type="ref"}). As there was no control group, however, the evidence that these increases are related to training, rather than reflecting general improvements in awareness and knowledge, is weak, and self‐reported outcomes may reflect courtesy bias. A two‐day training intervention was conducted in Nepal, augmented by printed materials, referral vouchers, and interactive meetings between pharmacy workers and abortion providers. The study also included refresher training after 10 months and an end‐line evaluation at one year. At baseline, knowledge of MA in both the intervention and control groups was high, which the authors speculated was due to recent NGO training in the area, but knowledge fell among the control group during the study, highlighting the need for training to be periodic (Tamang, Puri, Lama, and Shrestha [2015](#sifp12049-bib-0038){ref-type="ref"}).

The use of a call center to improve pharmacy worker knowledge was assessed in Bangladesh. Knowledge was greater among pharmacy workers who had contact with a call center (set up by an international NGO to provide information on MA) after adjusting for potential confounding factors (Reiss et al. [2015a](#sifp12049-bib-0030){ref-type="ref"}). The Bangladesh study also assessed whether knowledge was higher among pharmacy workers who reported receiving pharmaceutical company visits or training from an NGO; there was some evidence that NGO training had a positive effect. However, since this study did not collect baseline data, the associations cannot be assumed to be causal.

DISCUSSION {#sifp12049-sec-0110}
==========

The studies in this systematic review suggest that provision of abortifacients by pharmacy workers and drug sellers in LMICs is common, as is provision of medications to induce abortion without a prescription (including effective and ineffective drugs). The highest quality evidence of these findings relates to Mexico, India, Bangladesh, and Nepal, but there were studies of reasonable methodological quality from sub‐Saharan Africa (Nigeria, Zambia, Senegal, Kenya), Latin America (Peru and Dominican Republic), and Asia (India, Bangladesh, Vietnam, Nepal). However, in Latin America, there was a paucity of high‐quality recent studies (published in the last 5 years) from countries other than Mexico, and some studies from the 1990s are of limited relevance today. Use of standardized indicators and repeated cross‐sectional studies would improve comparability between regions and over time to assess trends in MA availability in pharmacies and drug shops.

In general, the review found that the information provided by individuals working in pharmacies and drug shops was poor, with many recommending ineffective drugs, few advising an effective regimen, and few giving information on potential complications and what to do if they occur. Poor‐quality products and information provision by pharmacies is not a problem unique to MA. Incorrect advice and inappropriate supply of medicines in LMIC pharmacies have been documented for health services ranging from childhood diarrhea to tuberculosis (Smith [2009](#sifp12049-bib-0036){ref-type="ref"}). However, stigma and legal restrictions related to abortion may create additional challenges for quality of pharmacy provision of MA, not least because drugs are often used off‐label. In Africa the reported level of provision (proportion of pharmacy workers/drug sellers who offered MA drugs/ mystery clients who were offered MA) was higher in less restrictive settings (i.e. Zambia), but this was not the case in other regions such as Latin America, where provision was relatively high despite legal restrictions. The highest levels of knowledge of the MA regimen were also found in settings where abortion was less legally restricted (India, Nepal).

We found only three studies that evaluated interventions to improve pharmacy worker knowledge or practice of MA, despite the search including unpublished grey literature. All three studies were in settings where abortion/menstrual regulation had few legal restrictions, suggesting that legal issues may be hindering interventions and research on this topic in other regions. The studies did not have rigorous evaluation designs, and two of them lacked a control group. The studies found that pharmacy worker training, with some form of follow up, can improve knowledge. One study suggested that call centers, but not pharmaceutical one‐to‐one education visits, may be effective in improving knowledge among pharmacy workers. The evidence for training is supported by two other systematic reviews which found that educational initiatives have positive impacts on pharmacy provision of general health services (Smith [2009](#sifp12049-bib-0036){ref-type="ref"}; Wafula and Goodman [2010](#sifp12049-bib-0041){ref-type="ref"}). However, the studies did not assess whether improved knowledge resulted in higher quality provision practice. Research suggests that increased knowledge of MA regimens may not result in improved counseling (Powell‐Jackson, Acharya, Filippi, and Ronsmans [2015](#sifp12049-bib-0028){ref-type="ref"}). Additionally, none of the studies in this review looked at the costs or cost‐effectiveness of the interventions; there are an estimated 210,000 registered and unregistered drug sellers in Bangladesh (Uzzal [2014](#sifp12049-bib-0040){ref-type="ref"}), and 40,000 in Vietnam (Minh, Huong, Byrkit, and Murray [2013](#sifp12049-bib-0024){ref-type="ref"}), so scaling up training initiatives to the national level may not be feasible in many LMICs. High mobility of pharmacies (either moving location or closing down) (Hendrickson et al. [2015](#sifp12049-bib-0018){ref-type="ref"}), high turnover of staff, and high numbers of informal drug sellers are also challenges to the feasibility of scaling up training initiatives. In this review, as in others (Smith [2009](#sifp12049-bib-0036){ref-type="ref"}; Wafula and Goodman [2010](#sifp12049-bib-0041){ref-type="ref"}), there was no evaluation of more innovative approaches to improving pharmacy performance, such as incentive structures, feedback, or regulatory mechanisms. Further evidence is needed on efficient ways of strengthening the information pharmacy workers receive about MA, such as one‐to‐one education meetings and telemedicine.

Most of the interventions in this review were targeted at changing pharmacy worker behavior. Evidence is also needed on the effectiveness of interventions to provide information directly to women who purchase MA drugs from pharmacies/drug shops and self‐administer the medications. The WHO task‐sharing guidelines for abortion recommend against pharmacy provision of MA, because of a lack of comparative evidence (World Health Organization [2012](#sifp12049-bib-0043){ref-type="ref"}), but recommend self‐management for sub‐tasks of MA in circumstances where women have access to appropriate information and emergency care. Directly providing women with the information they need to self‐manage a medical abortion, for example through telephone hotlines, may improve the outcomes of women who purchase MA from drug shops and reduce the potential harm of unsafe abortion. However, women may continue to purchase ineffective medicines sold as abortifacients from pharmacies and drug shops if effective MA drugs are not available or if they cannot afford the most effective medications and are sold an inferior product. Evaluations of strategies to reduce sales of unsafe, ineffective, and incorrect medications are also needed.

This review has a number of limitations. First, in the search process we found several relevant study abstracts but could not access full‐text reports, so these are necessarily excluded, as were some relevant studies that used only qualitative methods. We also found studies evaluating innovative interventions such as telemedicine for reducing risk from unsafe MA, but we could not include these studies as they were not directed exclusively at pharmacy or drug shop provision. The research field is small and we necessarily had to include studies that some of us had authored ourselves. To avoid potential ethical bias, the quality scoring was conducted only by non‐authors of the paper being reviewed, and were checked by a second external reviewer. The heterogeneity of the study designs and outcomes posed challenges for selecting an appropriate methodological appraisal tool, particularly for the intervention studies. The tool we used to assess the intervention studies---CASP---was designed to evaluate randomized controlled trials. Although we adapted the question wording, our use of this tool meant that the intervention studies (only one of which had a control group) were appraised relatively harshly. Trends over time, between countries, and across regions could not be clearly assessed given the variability of methods used, indicators measured, and locations where the studies took place. Because most studies included in the review were cross‐sectional, we could not assess within‐country temporal trends. We also were unable to assess the quality of products offered or sold because none of the studies tested products, and we were unable to compare product costs across studies given the lack of data. The issue of MA product quality has been addressed only to a limited degree and warrants further attention (Hall [2016](#sifp12049-bib-0016){ref-type="ref"}). The quality of studies selected was mixed, and intervention studies were not methodologically strong, often relying on small or convenience samples and using inadequate designs. This may reflect the challenge of conducting interventions and evaluations on a legally restricted practice. Finally, we included studies that reported on a number of different outcomes, making comparisons difficult.

CONCLUSION {#sifp12049-sec-0120}
==========

Availability of MA in pharmacies and drug shops in LMICs is common, and evidence suggests that women seek assistance from such outlets when faced with an unwanted pregnancy. Pharmacies can expand access to medications for MA, but they do not always provide the right products or effective regimens, and the quality of their knowledge and information provision is often poor. Despite increasing research, there is a lack of high‐quality evidence in many settings where abortion is more highly restricted. The use of pharmacies and drug shops as a first port of call for health care, and the poor quality of health care provided by pharmacy workers and drug sellers, are not limited to abortion. However, leveraging the benefits of pharmacies and drug shops, such as their perceived accessibility, affordability, and confidentiality, has great potential to reduce the harm caused by unsafe abortion. More innovative interventions and rigorous evaluations that include cost‐effectiveness are needed to build the evidence base on what works to improve provision through pharmacy workers and drug sellers and to increase women\'s access to information. To reduce the consequences of unsafe abortion, interventions cannot rely solely on pharmacy workers and drug sellers providing higher quality information, but should seek to ensure that women have direct access to the information they need to self‐administer medical abortion.
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